Allogene Therapeutics Inc at Cowen IO Next Summit (Virtual) Transcript
All right. Good morning or good afternoon, everyone. My name is Tyler Van Buren, and I'm a Senior Biotech analyst at Cowen. Thank you for joining us for Cowen's Sixth Annual IO Next Summit. For this next session, I'll be moderating a fireside chat with Allogene Therapeutics, a leader and pioneer in the AlloCell therapy space. It's my pleasure to introduce my friend, Eric Schmidt, Allogene's Chief Financial Officer. Eric, thank you for taking the time with us today.
Thank you, Tyler. Thanks to Cowen for hosting. Always a pleasure.
Questions & Answers
(Conference Instructions) Eric, let's go ahead and kick it off with a couple general questions. So the CD19 class of CAR T is annualizing at $2 billion and growing at a significant pace with recent second-line approvals. And then the BCMA class of CAR Ts is launching and will likely create another multibillion class of CAR T. So what's
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |